Leukemia

Published by: Nature Publishing Group  

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Levine
    Levine
  3. Stein
    Stein
  4. Curran
    Curran
  5. Gonen
    Gonen
  6. Kharas
    Kharas
  7. Koche
    Koche
  8. Park
    Park
  9. Rampal
    Rampal
  10. Shukla
    Shukla

Groups

  1. Adult Leukemia (17)
  2. Center for Hematologic Malignancies (17)
  3. Department of Medicine (17)
  4. Hematologic Malignancies, Division of (17)
  5. Executive Committee, Center for Hematologic Malignancies (4)
  6. GSK Faculty (4)
  7. Human Oncology and Pathogenesis Program (4)
  8. Tow Center for Developmental Oncology (TCDO) (4)
  9. Alumni (GSK) (1)
  10. Biostatistics Service (1)
Search Within
  1. "Martin Tallman"
Formats
  1. Journal Article (16)
  2. Review (1)
Groups
  1. Adult Leukemia (17)
  2. Center for Hematologic Malignancies (17)
  3. Department of Medicine (17)
  4. Hematologic Malignancies, Division of (17)
  5. Executive Committee, Center for Hematologic Malignancies (4)
  6. GSK Faculty (4)

More Groups

People
  1. Martin Tallman (17)
  2. Ross Levine (4)
  3. Jay Patel (3)
  4. Omar Abdel-Wahab (3)
  5. Eytan Stein (2)
  6. Andrei Krivtsov (1)

More People

Years
  1. 2022 (2)
  2. 2021 (4)
  3. 2019 (2)
  4. 2018 (1)
  5. 2017 (3)
  6. 2015 (3)

More Years

Publishers
  1. Nature Publishing Group (17)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
    Journal Article

    Jahn, N.; Jahn, E.; Saadati, M.; Bullinger, L.; Larson, R. A.; Ottone, T.; Amadori, S.; Prior, T. W.; Brandwein, J. M.; Appelbaum, F. R.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
    Journal Article

    Rücker, F. G.; Du, L.; Luck, T. J.; Benner, A.; Krzykalla, J.; Gathmann, I.; Voso, M. T.; Amadori, S.; Prior, T. W.; Brandwein, J. M.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603/RATIFY trial
    Journal Article

    Larson, R. A.; Mandrekar, S. J.; Huebner, L. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Döhner, K.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: Analysis from CALGB 10403 and the CIBMTR
    Journal Article

    Wieduwilt, M. J.; Stock, W.; Advani, A.; Luger, S.; Larson, R. A.; Tallman, M.; Appelbaum, F.; Zhang, M. J.; Bo-Subait, K.; Wang, H. L.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
    Review

    Grever, M.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S.; Blachly, J. S.; Call, T.; Cross, M.; Dearden, C.; Demeter, J.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Interferon alpha therapy in essential thrombocythemia and polycythemia vera — A systematic review and meta-analysis
    Journal Article

    Bewersdorf, J. P.; Giri, S.; Wang, R.; Podoltsev, N.; Williams, R. T.; Tallman, M. S.; Rampal, R. K.; Zeidan, A. M.; Stahl, M.
    Leukemia (2021)

    Fulltext@MSK | Save
  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
    Journal Article

    Pollyea, D. A.; Tallman, M. S.; de Botton, S.; Kantarjian, H. M.; Collins, R.; Stein, A. S.; Frattini, M. G.; Xu, Q.; Tosolini, A.; See, W. L.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): An alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
    Journal Article

    Ustun, C.; Le-Rademacher, J.; Wang, H. L.; Othus, M.; Sun, Z.; Major, B.; Zhang, M. J.; Storrick, E.; Lafky, J. M.; Chow, S.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • Molecular remission as a therapeutic objective in acute promyelocytic leukemia
    Journal Article

    Cicconi, L.; Fenaux, P.; Kantarjian, H.; Tallman, M.; Sanz, M. A.; Lo-Coco, F.
    Leukemia (2018)

    Fulltext@MSK | Save
  • Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
    Journal Article

    Kayser, S.; Krzykalla, J.; Elliott, M. A.; Norsworthy, K.; Gonzales, P.; Hills, R. K.; Baer, M. R.; Ráčil, Z.; Mayer, J.; Novak, J.; more...
    Leukemia (2017)

    Fulltext@MSK | Save

    • Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Leukemia 08876924 2020, The Author(s)
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2018, The Author(s)
    Leukemia 08876924 The Author(s), Under Exclusive Licence To Springer Nature Limited 2024
    Leukemia 08876924 The Author(s) 2024
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 14765551 Unknown
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 Nature Publishing Group
    Leukemia 08876924 2018, Springer Nature Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 14765551 Macmillan Publishers Limited
    Leukemia 08876924 2023, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 Unknown
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2020, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 2019, Springer Nature Limited
    Leukemia 0887-6924 Unknown
    Leukemia 0887-6924 Stockton Press
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2021, The Author(s)
    Leukemia 08876924 2021, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 2023, The Author(s)
    Leukemia 08876924 The Author(s) 2018
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2019, The Author(s)
    Leukemia 08876924 Macmillan Publishers Limited, Part of Springer Nature
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2018, Macmillan Publishers Limited, Part of Springer Nature
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2022, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2022, The Author(s)
    Leukemia 08876924 The Author(s)
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Macmillan Publishers Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 Macmillan Publishers Limited
    Leukemia (08876924) 2168-6181 Unknown
    Leukemia (08876924) 0732-183X Unknown
    Leukemia (08876924) 0887-6924 Unknown
    Leukemia (Basingstoke) 0887-6924 Unknown